Healthcare
AvenCell – SUCCESS PAGE – December 15, 2025
AvenCell Therapeutics is pioneering the next generation of cancer treatment with powerful, persistent, and switchable allogeneic CAR-T therapies
AvenCell Therapeutics is pioneering the next generation of cancer treatment with powerful, persistent, and switchable allogeneic CAR-T therapies
AvenCell Therapeutics is pioneering the next generation of cancer treatment with powerful, persistent, and switchable allogeneic CAR-T therapies
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.
Vantis Vascular is developing breakthrough tools to deliver game-changing outcomes in advanced vascular intervention
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.
Duo Oncology is a next-generation biotech company creating a nanomedicine platform that replaces chemotherapy for hard-to-treat cancers
Duo Oncology is a next-generation biotech company creating a nanomedicine platform that replaces chemotherapy for hard-to-treat cancers
Xgene is using its proprietary conjugate platform technology to provide highly effective non-opioid relief for acute and chronic pain
Xgene is using its proprietary conjugate platform technology to provide highly effective non-opioid relief for acute and chronic pain
Auctus Vertical Body Tethering has received a Breakthrough Device Designation and Humanitarian Device Exemption Pathway from the FDA
BrainScope has a pipeline that spans stroke, Alzheimer’s, concussion, and beyond, and is uniquely positioned in a $21B+ global market
Breakthru Medicine is developing precision cancer therapies targeting an $18B+ solid cancer market with massive unmet need